DOCSLIB.ORG

ATC Seznam (2019)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ATC Seznam (2019) ATCv 2019 ATCCode ATCDescription ATCDescriptionSI QA ALIMENTARY TRACT AND METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL IN PRESNOVE QA01 STOMATOLOGICAL PREPARATIONS ZDRAVILA V ZOBOZDRAVSTVU QA01A Stomatological preparations Zdravila v zobozdravstvu QA01AA Caries prophylactic agents Zdravila za zaščito pred zobnim kariesom QA01AA01 sodium fluoride natrijev fluorid QA01AA02 sodium monofluorophosphate natrijev monofluorofosfat QA01AA03 olaflur olaflur QA01AA04 stannous fluoride kositrov(II) fluorid QA01AA30 combinations kombinacije QA01AA51 sodium fluoride, combinations natrijev fluorid, kombinacije QA01AB Antiinfectives and antiseptics for local oral treatment Protimikrobne učinkovine in antiseptiki za lokalno oralno zdravljenje QA01AB02 hydrogen peroxide vodikov peroksid QA01AB03 chlorhexidine klorheksidin QA01AB04 amphotericin B amfotericin B QA01AB05 polynoxylin polinoksilin QA01AB06 domiphen domifen QA01AB07 oxyquinoline oksikinolin QA01AB08 neomycin neomicin QA01AB09 miconazole mikonazol QA01AB10 natamycin natamicin QA01AB11 various razne učinkovine QA01AB12 hexetidine heksetidin QA01AB13 tetracycline tetraciklin QA01AB14 benzoxonium chloride benzoksonijev klorid QA01AB15 tibezonium iodide tibezonijev jodid QA01AB16 mepartricin mepartricin QA01AB17 metronidazole metronidazol QA01AB18 clotrimazole klotrimazol QA01AB19 sodium perborate natrijev perborat QA01AB20 antiinfectives for local oral treatment, combinations protimikrobne učinkovine za lokalno oralno zdravljenje, kombinacije QA01AB21 chlortetracycline klortetraciklin QA01AB22 doxycycline doksiciklin QA01AB23 minocycline minociklin QA01AC Corticosteroids for local oral treatment Kortikosteroidi za lokalno oralno zdravljenje QA01AC01 triamcinolone triamcinolon QA01AC02 dexamethasone deksametazon QA01AC03 hydrocortisone hidrokortizon QA01AC54 prednisolone, combinations prednizolon, kombinacije QA01AD Other agents for local oral treatment Druga zdravila za lokalno oralno zdravljenje QA01AD01 epinephrine adrenalin QA01AD02 benzydamine benzidamin QA01AD05 acetylsalicylic acid acetilsalicilna kislina QA01AD06 adrenalone adrenalon QA01AD07 amlexanox amleksanoks QA01AD08 becaplermin bekaplermin QA01AD11 various razne učinkovine QA02 DRUGS FOR ACID RELATED DISORDERS ZDRAVILA ZA KISLINSKO POGOJENE BOLEZNI QA02A Antacids Antacidi QA02AA Magnesium compounds Magnezijeve spojine QA02AA01 magnesium carbonate magnezijev karbonat QA02AA02 magnesium oxide magnezijev oksid QA02AA03 magnesium peroxide magnezijev peroksid Stran 1 od 146 ATCv 2019 ATCCode ATCDescription ATCDescriptionSI QA02AA04 magnesium hydroxide magnezijev hidroksid QA02AA05 magnesium silicate magnezijev silikat QA02AA10 combinations kombinacije QA02AB Aluminium compounds Aluminijeve spojine QA02AB01 aluminium hydroxide aluminijev hidroksid QA02AB02 algeldrate algeldrat QA02AB03 aluminium phosphate aluminijev fosfat QA02AB04 dihydroxialumini sodium carbonate dihidroksialuminijev natrijev karbonat QA02AB05 aluminium acetoacetate aluminijev acetoacetat QA02AB06 aloglutamol aloglutamol QA02AB07 aluminium glycinate aluminijev glicinat QA02AB10 combinations kombinacije QA02AC Calcium compounds Kalcijeve spojine QA02AC01 calcium carbonate kalcijev karbonat QA02AC02 calcium silicate kalcijev silikat QA02AC10 combinations kombinacije QA02AD Combinations and complexes of aluminium, calcium and magnesium compounds Zdravila z aluminijem, kalcijem in magnezijem QA02AD01 ordinary salt combinations običajne kombinacije soli QA02AD02 magaldrate magaldrat QA02AD03 almagate almagat QA02AD04 hydrotalcite hidrotalcit QA02AD05 almasilate almasilat QA02AF Antacids with antiflatulents Antacidi s karminativi QA02AF01 magaldrate and antiflatulents magaldrat in karminativi QA02AF02 ordinary salt combinations and antiflatulents običajne kombinacije soli in antiflatulenti QA02AG Antacids with antispasmodics Antacidi s spazmolitiki QA02AH Antacids with sodium bicarbonate Antacidi z natrijevim hidrogenkarbonatom QA02AX Antacids, other combinations Antacidi, druge kombinacije QA02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (GERB) QA02BA H2-receptor antagonists Antagonisti histaminskih receptorjev H2 QA02BA01 cimetidine cimetidin QA02BA02 ranitidine ranitidin QA02BA03 famotidine famotidin QA02BA04 nizatidine nizatidin QA02BA05 niperotidine niperotidin QA02BA06 roxatidine roksatidin QA02BA07 ranitidine bismuth citrate ranitidin-bizmutov citrat (kompleks ranitidina in bizmutovega citrata) QA02BA08 lafutidine lafutidin QA02BA51 cimetidine, combinations cimetidin, kombinacije QA02BA53 famotidine, combinations famotidin, kombinacije QA02BB Prostaglandins Prostaglandini QA02BB01 misoprostol mizoprostol QA02BB02 enprostil enprostil QA02BC Proton pump inhibitors Zaviralci protonske črpalke QA02BC01 omeprazole omeprazol QA02BC02 pantoprazole pantoprazol QA02BC03 lansoprazole lansoprazol QA02BC04 rabeprazole rabeprazol QA02BC05 esomeprazole esomeprazol QA02BC06 dexlansoprazole dekslansoprazol QA02BC07 dexrabeprazole deksrabeprazol QA02BC53 lansoprazole, combinations lansoprazol, kombinacije Stran 2 od 146 ATCv 2019 ATCCode ATCDescription ATCDescriptionSI QA02BC54 rabeprazole, combinations rabeprazol, kombinacije QA02BD Combinations for eradication of Helicobacter pylori Kombinacije učinkovin za zdravljenje okužb z bakterijo Helicobacter pylori QA02BD01 omeprazole, amoxicillin and metronidazole omeprazol, amoksicilin in metronidazol QA02BD02 lansoprazole, tetracycline and metronidazol lansoprazol, tetraciklin in metronidazol QA02BD03 lansoprazole, amoxicillin and metronidazol lansoprazol, amoksicilin in metronidazol QA02BD04 pantoprazole, amoxicillin and clarithromycin pantoprazol, amoksicilin in klaritromicin QA02BD05 omeprazole, amoxicillin and clarithromycin omeprazol, amoksicilin in klaritromicin QA02BD06 esomeprazole, amoxicillin and clarithromycin esomeprazol, amoksicilin in klaritromicin QA02BD07 lansoprazole, amoxicillin and clarithromycin lansoprazol, amoksicilin in klaritromicin QA02BD08 bismuth subcitrate, tetracycline and metronidazole bizmutov subcitrat, tetraciklin in metronidazol QA02BD09 lansoprazole, clarithromycin and tinidazole lansoprazol, lkaritromicin in tinidazol QA02BD10 lansoprazole, amoxicillin and levofloxacin lansoprazol, amoksicilin in levofloksacin QA02BD11 pantoprazole, amoxicillin, clarithromycin and metronidazole pantoprazol, amoksicilin, klaritromicin in metronidazol QA02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Druga zdravila za zdravljenje peptične razjede in gastroezofagealne refluksne bolezni (GERB) QA02BX01 carbenoxolone karbenoksolon QA02BX02 sucralfate sukralfat (aluminijev saharozni sulfat) QA02BX03 pirenzepine pirenzepin QA02BX04 methiosulfonium chloride metiosulfonijev klorid QA02BX05 bismuth subcitrate bazični bizmutov citrat QA02BX06 proglumide proglumid QA02BX07 gefarnate gefarnat QA02BX08 sulglicotide sulglikotid QA02BX09 acetoxolone acetoksolon QA02BX10 zolimidine zolimidin QA02BX11 troxipide troksipid QA02BX12 bismuth subnitrate bazični bizmutov nitrat QA02BX13 alginic acid alginska kislina QA02BX14 rebamipide rebamipid QA02BX51 carbenoxolone, combinations excl. psycholeptics karbenoksolon, kombinacije brez psiholeptikov QA02BX71 carbenoxolone, combinations with psycholeptics karbenoksolon, kombinacije s psiholeptiki QA02BX77 gefarnate, combinations with psycholeptics gefarnat, kombinacije s psiholeptiki QA02X Other drugs for acid related disorders Druga zdravila za kislinsko pogojene bolezni QA03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ZDRAVILA ZA ZDRAVLJENJE GASTROINTESTINALNIH FUNKCIONALNIH MOTENJ QA03A Drugs for functional gastrointestinal disorders Zdravila za zdravljenje gastrointestinalnih funkcionalnih motenj QA03AA Synthetic anticholinergics, esters with tertiary amino group Sintezni antiholinergiki, estri s terciarno aminoskupino QA03AA01 oxyphencyclimine oksifenciklimin QA03AA03 camylofin kamilofin QA03AA04 mebeverine mebeverin QA03AA05 trimebutine trimebutin QA03AA06 rociverine rociverin QA03AA07 dicycloverine dicikloverin QA03AA08 dihexyverine diheksiverin QA03AA09 difemerine difemerin QA03AA30 piperidolate piperidolat QA03AB Synthetic anticholinergics, quaternary ammonium compounds Sintezni antiholinergiki s kvaterno amonijevo skupino QA03AB01 benzilone benzilon QA03AB02 glycopyrronium glikopironium QA03AB03 oxyphenonium oksifenonium QA03AB04 penthienate pentienat QA03AB05 propantheline propantelin QA03AB06 otilonium bromide otilonijev bromid QA03AB07 methantheline metantelin Stran 3 od 146 ATCv 2019 ATCCode ATCDescription ATCDescriptionSI QA03AB08 tridihexethyl tridiheksetil QA03AB09 isopropamide izopropamid QA03AB10 hexocyclium heksociklium QA03AB11 poldine poldin QA03AB12 mepenzolate mepenzolat QA03AB13 bevonium bevonium QA03AB14 pipenzolate pipenzolat QA03AB15 diphemanil difemanil QA03AB16 (2-benzhydryloxyethyl)diethyl-methylammonium iodide (2-benzhidriloksietil)dietilmetilamonijev jodid QA03AB17 tiemonium iodide tiemonijev jodid QA03AB18 prifinium bromide prifinijev bromid QA03AB19 timepidium bromide timepedijev bromid QA03AB21 fenpiverinium fenpiverinium QA03AB53 oxyphenonium, combinations oksifenonium, kombinacije QA03AB90 benzetimide benzetimid QA03AB92 carbachol karbahol QA03AB93 neostigmin neostigmin QA03AC Synthetic antispasmodics, amides with tertiary amines Sintezni spazmolitiki, amidi s terciarno aminoskupino QA03AC02 dimethylaminopropionylphenothiazine dimetilaminopropionilfenotiazin QA03AC04 nicofetamide nikofetamid QA03AC05 tiropramide
Load more

Recommended publications
  • The Chemotherapy of Malignant Disease -Practical and Experimental Considerations
    Postgrad Med J: first published as 10.1136/pgmj.41.475.268 on 1 May 1965. Downloaded from POSTGRAD. MED. J. (1965), 41,268 THE CHEMOTHERAPY OF MALIGNANT DISEASE -PRACTICAL AND EXPERIMENTAL CONSIDERATIONS JOHN MATTHIAS, M.D., M.R.C.P., F.F.A., R.C.S. Physician, The Royal Marsden Hospital, London, S.W.3. THE TERM chemotherapy was introduced by positively charged alkyl (CH2) radicles of Ehrlich to describe the specific and effective the agent. treatment of infectious disease by chemical (a) The nitrogen mustards: mustine (HN2 substances. It is currently also applied to the 'nitrogen mustard', mechlorethamine, treatment of malignant disease. Unfortunately mustargen), trimustine (Trillekamin no aspect of tumour metabolism has been HN3), chlorambucil (Leukeran, phenyl discovered which has allowed the development butyric mustard), melphalan (Alkeran, of drugs capable of acting specifically upon the phenyl alanine mustard), uramustine malignant cell, so that cytotoxic drugs also (Uracil mustard), cyclophosphamide affect normal cells to a greater or lesser degree. (Endoxan or Cytoxan), mannomustine The most susceptible or sensitive of the normal (DegranoO). tissues are those with the highest rates of cell (b) The ethylenamines: tretamine (trie- turnover and include the haemopoietic and thanomelamine, triethylene melamine, lympho-reticular tissues, the gastro-intestinal TEM), thiotepa (triethylene thiopho- the the testis and the hair epithelium, ovary, sphoramide), triaziquone (Trenimon).by copyright. follicles. (c) The epoxides: triethyleneglycoldigly- Cancer chemotherapy may be said to encom- cidyl ether (Epodyl). pass all treatments of a chemical nature (d) The sulphonic acid esters: busulphan administered to patients with the purpose of (Myleran), mannitol myleran. restricting tumour growth or destroying tumour 2.
    [Show full text]
  • WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: A61K 31/53 (2006 .01) A61P 35/00 (2006 .0 1) C07D 251/40 (2006.01) (21) International Application Number: PCT/US20 18/024 134 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,585 24 March 2017 (24.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Devenport Av enue, Berkeley, CA 94619 (US). ANDERSON, Kimberly, E.; 8 Marchant Court, Kensington, CA 94707 (US). (74) Agent: LEE, Joohee et al; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 021 11 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • US 2006/0165744 A1 Jamil Et Al
    US 2006O165744A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0165744 A1 Jamil et al. (43) Pub. Date: Jul. 27, 2006 (54) COMBINATION LIPOSOMAL Related U.S. Application Data FORMULATIONS (60) Provisional application No. 60/472.664, filed on May (75) Inventors: Haris Jamil, Libertyville, IL (US); 22, 2003. Provisional application No. 60/495,260, Imran Ahmad, Wadsworth, IL (US); filed on Aug. 13, 2003. Zafeer Ahmad, Gurnee, IL (US); Gopal Anyarambhatla, Decatur, IL Publication Classification (US) (51) Int. Cl. AOIN 25/00 (2006.01) Correspondence Address: A 6LX 9/27 (2006.01) LEYDIG VOIT & MAYER, LTD CI2N 5/88 (2006.01) TWO PRUDENTIAL PLAZA, SUITE 4900 (52) U.S. Cl. ........................... 424/405; 424/450: 435/.458 18O NORTH STETSON AVENUE CHICAGO, IL 60601-6780 (US) (57) ABSTRACT (73) Assignee: NeoPharm, Inc, Lake Forest, IL (US) The present invention provides a composition comprising a physiologically acceptable carrier and two or more agents encapsulated in a liposome, wherein the combination of the (21) Appl. No.: 10/558,159 two or more agents possess the following properties: (1) cytotoxicity to tumor cells, (2) nutritional properties, (3) use in application to nails, hair, skin or lips or (4) activity against (22) PCT Filed: May 22, 2004 parasites and insects. The invention also provides a method of making such a composition. The invention further pro vides a method of treating cancer when the combination of (86). PCT No.: PCT/USO4/16413 the two or more agents is cytotoxic to tumor cells. US 2006/01 65 744 A1 Jul. 27, 2006 COMBINATION LIPOSOMAIL FORMULATIONS more agents (e.g., drugs or other active agents) is cytotoxic to tumor cells, and a physiologically acceptable carrier.
    [Show full text]
  • Covalent Protein Adduction of Nitrogen Mustards and Related Compounds Vanessa R
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 2-28-2014 Covalent Protein Adduction of Nitrogen Mustards and Related Compounds Vanessa R. Thompson Florida International University, [email protected] DOI: 10.25148/etd.FI14040835 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Amino Acids, Peptides, and Proteins Commons, and the Analytical Chemistry Commons Recommended Citation Thompson, Vanessa R., "Covalent Protein Adduction of Nitrogen Mustards and Related Compounds" (2014). FIU Electronic Theses and Dissertations. 1152. https://digitalcommons.fiu.edu/etd/1152 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida COVALENT PROTEIN ADDUCTION OF NITROGEN MUSTARDS AND RELATED COMPOUNDS A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Vanessa Thompson 2014 To: Dean Kenneth G. Furton College of Arts and Sciences This dissertation, written by Vanessa Thompson, and entitled Covalent Protein Adduction of Nitrogen Mustards and Related Compounds, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Fenfei Leng _______________________________________ Watson Lees _______________________________________ Dietrich Lorke _______________________________________ Bruce McCord _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: February 27, 2014 The dissertation of Vanessa Thompson is approved.
    [Show full text]
  • Recent Advancements in Uracil and 5-Fluorouracil Hybrids As Potential Anticancer Agents: a Review
    Journal of Applied Pharmaceutical Science Vol. 10(02), pp 129-146, February, 2020 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2020.102019 ISSN 2231-3354 Recent advancements in Uracil and 5-Fluorouracil hybrids as potential anticancer agents: A review Mohit Sanduja*, Jyoti Gupta, Tarun Virmani School of Pharmaceutical Sciences, MVN University, Palwal-121105, India. ARTICLE INFO ABSTRACT Received on: 01/10/2019 Cancer is the most dreadful disease and the second main cause of death worldwide. The continuous developments have Accepted on: 19/12/2019 been going on in order to design potent molecules such that this leading cause of death can be dealt with. In order to Available online: 05/02/2020 decrease the level of toxicity and to improve the selectivity of drugs toward cancer targets, the development of hybrid molecules has become the center of research, and scientists are doing timeless efforts to generate such a hybrid which has got no comparison with the previous developments. The heterocyclic moiety Uracil and many of its derivatives Key words: were already exposed as promising anticancer agents. Moreover, coupling of Uracil and 5-Fluorouracil (5-FU) with Uracil, 5-Fluorouracil, cancer, different pharmacophores has been proven to be an excellent strategy against cancer. Hence, the present review is an hybrid, anticancer agents, cell effort to collectively represent all the earlier and recent developments of Uracil and 5-FU hybrids reported to have a lines. significant anticancer profile. Expectantly, we can assure that this article can serve as the basis for further developments in Uracil and 5-FU hybrids and will surely motivate the medicinal chemists for producing unique anticancer drug.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - [email protected] HEIKKI KUUSANMÄKI - [email protected] Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • ANTINEOPLASTIC AGENTS (Part-II) by Mrs
    ANTINEOPLASTIC AGENTS (Part-II) By Mrs. Rashmi Kumari Assistant Professor PG Department of Chemistry Magadh University Bodh-Gaya Stream: M.Sc. Organic Chemistry (Sem.-IV) Classes of Antineoplastic Agents • Alkylating Agents • Antimetabolites • Natural Products • Hormonal Agents • Anti Tumor Antibiotics • Miscellaneous Agents • Works by affecting DNA synthesis and function. Alkylating Agents • Alkylating agents • Nitrogen Mustard: • Uracil Mustard, • Melphalan • Ethylamine Derivatives • Nitrosourea • Alkyl Sulphonates • Platinum Complexes Mode of Action of Alkylating Agents Nitrogen Mustards • They substitute alkyl group for H forming DNA adduct. • Functional group can form inter/intra stand crosslink in DNA Mode of Action: Nitrogen Mustards Structure Activity Relationship • R can be either aliphatic or aromatic. • Case-1. R=Aliphatic Substituent • R an aliphatic substituent will push electrons to the amine. This electronic enrichment enhances the nucleophilic character of the lone pair of electrons and increases the speed of SN2. Structure Activity Relationship • Case-2. R=Aromatic Substituent • An aromatic substituent will stabilize the lone pair of electrons through resonance.This resonance slows the rate of intermolecular nucleophilic attack azridinium ion formation and DNA alkylation. The highest stability of aromatic mustard not only permits oral administration but also attenuate the severity of side effects. Uracil Mustard • Uracil Mustard (Uramustine) • Used in Lymphatic Malignancies • Selectively inhibits the synthesis of DNA promotes cell death of cancer cells. Structure of Uracil Mustard Synthetic route: SOCl2 I II Melphalan Melphalan I II III V VI IV Antimetabolites • Antimetabolites are structurally related to normal compounds that exist within the cell.t • Antimetabolites generally interfere with the availability of normal purine pyrimidine nucleotide precursors either by inhibiting their synthesis or by competing with them in DNA or RNA synthesis.
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptMed Res Author Manuscript Rev. Author manuscript; Author Manuscript available in PMC 2017 January 01. Published in final edited form as: Med Res Rev. 2016 January ; 36(1): 32–91. doi:10.1002/med.21377. Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates Zhiyan Xiao1,2,*, Susan L. Morris-Natschke3, and Kuo-Hsiung Lee3,4,* 1Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China 2State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China 3Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568, USA 4Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan Abstract Natural products have made significant contribution to cancer chemotherapy over the past decades and remain an indispensable source of molecular and mechanistic diversity for anticancer drug discovery. More often than not, natural products may serve as leads for further drug development rather than as effective anticancer drugs by themselves. Generally, optimization of natural leads into anticancer drugs or drug candidates should not only address drug efficacy, but also improve ADMET profiles and chemical accessibility associated with the natural leads. Optimization strategies involve direct chemical manipulation of functional groups, structure-activity relationship-directed optimization and pharmacophore-oriented molecular design based on the natural templates.
    [Show full text]
  • Pharmaceutical Waste Identification Checklist – Surgical Center
    Hazardous Drug Disposal Service Pharmaceutical Waste Identification Checklist – Surgical Center The U.S. Environmental Protection Agency (EPA) requires all businesses to evaluate waste materials, make a waste determination through “waste characterization”, and determine the amount of hazardous waste (per the Resource Conservation and Recovery Act – RCRA)they generate in a month prior to disposal. This is required to properly identify generator status of either Conditionally Exempt Small Quantity Generator (CESQG), Small Quantity Generator (SQG) or Large Quantity Generator (LQG) which will have varying requirements.1 This requirement extends to waste pharmaceuticals being disposed of by healthcare facilities. Stericycle has developed this checklist as an assessment tool to help healthcare facilities identify their pharmaceutical wastes (unused portions of left over, outdated, or sample drugs) and dispose of them appropriately. As always, you should refer to your state or local regulatory agency’s requirements to determine the best solution for your unique needs. State or local regulations may be more stringent or different than the EPA requirements. 1Source: http://www.epa.gov/rcra/resource-conservation-and-recovery-act-rcra-overview SECTION 1: Identifying Compatible Pharmaceutical Waste This partial list of compatible pharmaceutical waste denotes pharmaceutical items that can be placed together in the same container for disposal without risk of a chemical reaction. CHECK ANY OF THE FOLLOWING THAT YOU CARRY: 1. Anesthesia/Topical: 4. Dermatology: 7. Ophthalmology: Chloroform Fluocinonide Topical, Lidex Blephamide Isoflurane/Desflurane Fluorescein Sodium Fml S.o.p, Fluoromethalone Glycopyrrolate Bromide Lice Treatment Shampoos, Nix Neomycin/Polymyxin/ Phisohex Lindane Shampoo Or Lotion Dexamethasone Sevoflurane Resorcinol Neo-Synephrine Silvadene, Silver Sulfadiazine Selenium Sulfide, Dandrex, Viroptic, Trifluridine 2.
    [Show full text]
  • Hazardous Drug Acknowledgement Statement
    Hazardous Drug Handling Statement Hazardous Drug Acknowledgement Statement I understand that working with hazardous drugs in a pharmacy healthcare setting might cause health issues such as rashes, infertility, miscarriage, birth defects, and possibly cancer. I understand that the accidental exposure to some of these drugs might additionally cause irritation or damage to skin, eyes, or other exposed body parts. I understand that the handling of bodily fluids (urine, feces, sweat, and vomit) or bodily- fluid- contaminated clothing, dressing, linens, and other materials comes with potential exposure to hazardous drugs. I understand that the pharmacy OneWorld will follow reasonable policies and procedures in order to minimize my exposure to these drugs in accordance with commonly available information and guidance by such entities as the FDA and OSHA. I understand that the pharmacy OneWorld will also provide for safety measures and appropriate personal protective equipment to help limit my exposure to, or limit the results of, accidental exposure to such drugs. I also understand that these policies and procedures will be routinely reviewed and revised as needed in light of new information. I have been provided with training concerning hazardous drugs, and have passed a test verifying my understanding of key information concerning them. I understand that similar training will be repeated at least annually. __________________________________________ __________________________ Printed Employee Name Date __________________________________________
    [Show full text]
  • Evolution of Nitrogen-Based Alkylating Anticancer Agents
    processes Review Evolution of Nitrogen-Based Alkylating Anticancer Agents Fredrik Lehmann 1,* and Johan Wennerberg 2 1 Oncopeptides AB, Västra Trädgårdsgatan 15, SE-111 53 Stockholm, Sweden 2 Red Glead Discovery AB, Scheeletorget 1, 223 63 Lund, Sweden; [email protected] * Correspondence: [email protected]; Tel.: +46-(0)861-520-40 Abstract: Despite the significant progress in anticancer drug development over recent years, there is a vital need for newer agents with unique, but still effective, mechanisms of action in order to treat the disease, particularly the highly aggressive and drug-resistant types. Alkylating agents, in particular nitrogen-based alkylators, are commonly used to treat hematological and solid malignancies; they exert their antineoplastic effects at all phases of the cell cycle and prevent reproduction of tumor cells. Certain alkylating agents have been designed to be more lipophilic, enabling the compound to penetrate the cell and enhance its alkylating activity against tumors. This review details the evolution of currently available alkylating agents and their profiles, with a focus on nitrogen-based alkylating agents, as important anticancer therapy strategies. Keywords: alkylating agents; alkylators; antineoplastic agents; cytotoxicity; lipophilicity; nitro- gen mustard 1. Introduction It is a well-known fact that cancer is a major worldwide health issue, threatening Citation: Lehmann, F.; Wennerberg, J. human health with increasing incidence and mortality. According to the World Health Evolution of Nitrogen-Based Organization (WHO), cancer is the second leading cause of deaths globally, after cardio- Alkylating Anticancer Agents. vascular disease [1]. There has been significant progress in the development of anticancer Processes 2021, 9, 377.
    [Show full text]